Aurinia Pharmaceuticals Inc. (AUPH)

Market Cap	2.13B +93.0%
Revenue (ttm)	283.06M +20.4%
Net Income	287.20M +4,893.1%
EPS	2.07 +5,075.0%
Shares Out	132.97M
PE Ratio	7.75
Forward PE	19.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754,507
Open	16.07
Previous Close	15.83
Day's Range	15.89 - 16.19
52-Week Range	7.29 - 16.54
Beta	1.52
Analysts	Buy
Price Target	17.25 (+7.48%)
Earnings Date	May 11, 2026

About AUPH

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Can...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 1999
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: AUPH
• Website: https://www.auriniapharma.com

Financial Performance

In 2025, Aurinia Pharmaceuticals's revenue was $283.06 million, an increase of 20.38% compared to the previous year's $235.13 million. Earnings were $287.20 million, an increase of 4893.08%.

Analyst Summary

According to 4 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 7.48% from the latest price.

Price Target

$17.25

(7.48% upside)

Analyst Consensus: Buy